Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Thomas Morrison to Antibodies, Viral

This is a "connection" page, showing publications Thomas Morrison has written about Antibodies, Viral.

 
Connection Strength
 
 
 
1.397
 
  1. Lucas CJ, Davenport BJ, Carpentier KS, Tinega AN, Morrison TE. Two Conserved Phenylalanine Residues in the E1 Fusion Loop of Alphaviruses Are Essential for Viral Infectivity. J Virol. 2022 05 11; 96(9):e0006422.
    View in: PubMed
    Score: 0.156
  2. Huey L, Andersen G, Merkel PA, Morrison TE, McCarthy M, DomBourian MG, Annen K, Dawson ED, Rowlen KL, Knight V. Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma. J Immunol Methods. 2021 10; 497:113104.
    View in: PubMed
    Score: 0.148
  3. Annen K, Morrison TE, DomBourian MG, McCarthy MK, Huey L, Merkel PA, Andersen G, Schwartz E, Knight V. Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors. Transfusion. 2021 04; 61(4):1148-1159.
    View in: PubMed
    Score: 0.143
  4. Powell LA, Fox JM, Kose N, Kim AS, Majedi M, Bombardi R, Carnahan RH, Slaughter JC, Morrison TE, Diamond MS, Crowe JE. Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease. PLoS Pathog. 2020 05; 16(5):e1008517.
    View in: PubMed
    Score: 0.136
  5. Davenport BJ, Bullock C, McCarthy MK, Hawman DW, Murphy KM, Kedl RM, Diamond MS, Morrison TE. Chikungunya Virus Evades Antiviral CD8+ T Cell Responses To Establish Persistent Infection in Joint-Associated Tissues. J Virol. 2020 04 16; 94(9).
    View in: PubMed
    Score: 0.135
  6. McCarthy MK, Morrison TE. Blocking the Exit: CHIKV Neutralizing Antibodies Nip Viral Egress in the Bud. Cell Host Microbe. 2018 09 12; 24(3):328-330.
    View in: PubMed
    Score: 0.121
  7. Hawman DW, Fox JM, Ashbrook AW, May NA, Schroeder KMS, Torres RM, Crowe JE, Dermody TS, Diamond MS, Morrison TE. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence. Cell Rep. 2016 08 02; 16(5):1326-1338.
    View in: PubMed
    Score: 0.105
  8. Halemano K, Barrett BS, Heilman KJ, Morrison TE, Santiago ML. Requirement for Fc effector mechanisms in the APOBEC3/Rfv3-dependent neutralizing antibody response. J Virol. 2015 Apr; 89(7):4011-4.
    View in: PubMed
    Score: 0.094
  9. Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, Denton M, Legasse AW, Smith PP, Johnson S, Axthelm MK, Vanlandingham DL, Streblow DN, Higgs S, Morrison TE, Diamond MS. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol. 2014 Aug; 88(15):8213-26.
    View in: PubMed
    Score: 0.090
  10. Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond MS, Morrison TE. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. J Virol. 2013 Dec; 87(24):13878-88.
    View in: PubMed
    Score: 0.086
  11. Windsor WJ, Knight V, Merkel PA, Lamb MM, Tucker HR, Carson K, Howard KM, Yates JL, Santiago ML, McCarthy MK, Morrison TE, Kedl RM, Frazer-Abel A, Guo K, Andersen G, Huey L, Barrett BS, Col?n-Franco JM, Lee WT, Chu MC. COVID-19 Serology Control Panel Using the Dried-Tube Specimen Method. Am J Trop Med Hyg. 2022 01 07; 106(2):562-565.
    View in: PubMed
    Score: 0.038
  12. Schultz JS, McCarthy MK, Rester C, Sabourin KR, Annen K, DomBourian M, Eisenmesser E, Frazer-Abel A, Knight V, Jaenisch T, Morrison TE, Rochford R, Kedl RM. Development and Validation of a Multiplex Microsphere Immunoassay Using Dried Blood Spots for SARS-CoV-2 Seroprevalence: Application in First Responders in Colorado, USA. J Clin Microbiol. 2021 05 19; 59(6).
    View in: PubMed
    Score: 0.037
  13. Powers JM, Haese NN, Denton M, Ando T, Kreklywich C, Bonin K, Streblow CE, Kreklywich N, Smith P, Broeckel R, DeFilippis V, Morrison TE, Heise MT, Streblow DN. Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses. PLoS Negl Trop Dis. 2021 04; 15(4):e0009308.
    View in: PubMed
    Score: 0.036
  14. Taylor SC, Hurst B, Charlton CL, Bailey A, Kanji JN, McCarthy MK, Morrison TE, Huey L, Annen K, DomBourian MG, Knight V. A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection. J Clin Microbiol. 2021 03 19; 59(4).
    View in: PubMed
    Score: 0.036
  15. Sabourin KR, Schultz J, Romero J, Lamb MM, Larremore D, Morrison TE, Frazer-Abel A, Zimmer S, Kedl RM, Jaenisch T, Rochford R. Risk Factors of SARS-CoV-2 Antibodies in Arapahoe County First Responders-The COVID-19 Arapahoe SErosurveillance Study (CASES) Project. J Occup Environ Med. 2021 03 01; 63(3):191-198.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)